Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non–Small Cell Lung Cancer
Shun Lü, Wei Zhang, Lin Wu, et al.
JAMA (2024) Vol. 331, Iss. 3, pp. 201-201
Open Access | Times Cited: 138

Showing 1-25 of 138 citing articles:

Perioperative Nivolumab in Resectable Lung Cancer
Tina Cascone, Mark M. Awad, Jonathan Spicer, et al.
New England Journal of Medicine (2024) Vol. 390, Iss. 19, pp. 1756-1769
Closed Access | Times Cited: 125
Non-small-cell lung cancer
Lizza E.L. Hendriks, Jordi Remón, C. Faivre‐Finn, et al.
Nature Reviews Disease Primers (2024) Vol. 10, Iss. 1
Closed Access | Times Cited: 43
Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable in NSCLC
Jacobi Hines, Robert B. Cameron, Alessandra Esposito, et al.
Journal of Thoracic Oncology (2024) Vol. 19, Iss. 7, pp. 1108-1116
Open Access | Times Cited: 27
Association between pretreatment emotional distress and immune checkpoint inhibitor response in non-small-cell lung cancer
Yue Zeng, Chunhong Hu, Yizheng Li, et al.
Nature Medicine (2024) Vol. 30, Iss. 6, pp. 1680-1688
Open Access | Times Cited: 23
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial
Jonathan Spicer, Marina Chiara Garassino, Heather A. Wakelee, et al.
The Lancet (2024) Vol. 404, Iss. 10459, pp. 1240-1252
Closed Access | Times Cited: 22
Neoadjuvant SHR-1701 with or without chemotherapy in unresectable stage III non-small-cell lung cancer: A proof-of-concept, phase 2 trial
Qing Zhou, Yi Pan, Xue‐Ning Yang, et al.
Cancer Cell (2024) Vol. 42, Iss. 7, pp. 1258-1267.e2
Open Access | Times Cited: 12
Neoadjuvant camrelizumab (an anti-PD-1 antibody) plus chemotherapy or apatinib (a VEGFR-2 inhibitor) for initially unresectable stage II–III non-small-cell lung cancer: a multicentre, two-arm, phase 2 exploratory study
Haoran Xia, Han Zhang, Zheng Ruan, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 10
Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial
Dongsheng Yue, Wenxiang Wang, Hongxu Liu, et al.
The Lancet Respiratory Medicine (2024)
Closed Access | Times Cited: 10
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
Fei Zhou, Haoyue Guo, Yang Xia, et al.
Nature Reviews Clinical Oncology (2024)
Closed Access | Times Cited: 10
Immunotherapy in resectable NSCLC: Answering the question or questioning the answer?
Si‐Yang Liu, Weineng Feng, Yi‐Long Wu
Cancer Cell (2024) Vol. 42, Iss. 5, pp. 727-731
Closed Access | Times Cited: 8
High CD38 expression defines a mitochondrial function-adapted CD8+ T cell subset with implications for lung cancer immunotherapy
Lei-lei Lv, Jiawei Zhai, Jinrui Wu, et al.
Cancer Immunology Immunotherapy (2025) Vol. 74, Iss. 2
Open Access | Times Cited: 1
Immunotherapy in Oncogene-Addicted NSCLC: Evidence and Therapeutic Approaches
Lorenzo Foffano, Elisa Bertoli, Martina Bortolot, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 2, pp. 583-583
Open Access | Times Cited: 1
Is pathological response an adequate surrogate marker for survival in neoadjuvant therapy with immune checkpoint inhibitors?
K Sugiyama, Anderley Gordon, Sanjay Popat, et al.
ESMO Open (2025) Vol. 10, Iss. 2, pp. 104122-104122
Closed Access | Times Cited: 1
Anti-PD1 based precision induction therapy in unresectable stage III non-small cell lung cancer: a phase II umbrella clinical trial
Chengxiang Yi, Dongliang Bian, Jue Wang, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access | Times Cited: 1
Neoadjuvant or Perioperative Approach in Lung Cancer
Marina Chiara Garassino, Valter Torri
New England Journal of Medicine (2024) Vol. 390, Iss. 19, pp. 1816-1818
Closed Access | Times Cited: 7
Neoadjuvant Chemoimmunotherapy Complicates Subsequent Surgical Resection and Adjuvant Immunotherapy Is Preferable From the Surgical Standpoint
Paula A. Ugalde, Valérie Lacroix, Paul Van Schil
Journal of Thoracic Oncology (2024) Vol. 19, Iss. 6, pp. 858-861
Closed Access | Times Cited: 7
Multi-omic profiling highlights factors associated with resistance to immuno-chemotherapy in non-small-cell lung cancer
Yilv Yan, Dongqing Sun, Junjie Hu, et al.
Nature Genetics (2024)
Closed Access | Times Cited: 7
Stereotactic body radiotherapy with sequential tislelizumab and chemotherapy as neoadjuvant therapy in patients with resectable non-small-cell lung cancer in China (SACTION01): a single-arm, single-centre, phase 2 trial
Ze-Rui Zhao, Shiliang Liu, Ting Zhou, et al.
The Lancet Respiratory Medicine (2024) Vol. 12, Iss. 12, pp. 988-996
Closed Access | Times Cited: 6
Perioperative Immunotherapy for Non-Small Cell Lung Cancer: Practical Application of Emerging Data and New Challenges
Angelica D’Aiello, Brendon M. Stiles, Nitin Ohri, et al.
Clinical Lung Cancer (2024) Vol. 25, Iss. 3, pp. 197-214
Closed Access | Times Cited: 5
An Updated Review of Management of Resectable Stage III NSCLC in the Era of Neoadjuvant Immunotherapy
Saurav Verma, Daniel Breadner, Abhenil Mittal, et al.
Cancers (2024) Vol. 16, Iss. 7, pp. 1302-1302
Open Access | Times Cited: 5
Early-Stage Non-Small Cell Lung Cancer: New Challenges with Immune Checkpoint Blockers and Targeted Therapies
Pernelle Lavaud, Martina Bortolot, Lodovica Zullo, et al.
Cancers (2024) Vol. 16, Iss. 16, pp. 2779-2779
Open Access | Times Cited: 5
Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial
Mariano Provencio, Ernest Nadal, Amelia Insa, et al.
The Lancet Oncology (2024)
Open Access | Times Cited: 5
Improved event-free survival after complete or major pathologic response in patients with resectable NSCLC treated with neoadjuvant chemoimmunotherapy regardless of adjuvant treatment: a systematic review and individual patient data meta-analysis
Daniele Marinelli, A. Nuccio, Alessandro Di Federico, et al.
Journal of Thoracic Oncology (2024)
Closed Access | Times Cited: 4
Neoadjuvant immunotherapy strategies for resectable non-small cell lung cancer (NSCLC): Current evidence among special populations and future perspectives
Claudia Parisi, Pamela Abdayem, Marco Tagliamento, et al.
Cancer Treatment Reviews (2024) Vol. 131, pp. 102845-102845
Closed Access | Times Cited: 4
Racial/ethnic differences in survival and treatment response with PD-1/PD-L1 inhibitors in resectable non-small cell lung cancer: a meta-analysis of randomized controlled trials
Francisco Cézar Aquino de Moraes, Eric Pasqualotto, Anna Luíza Soares de Oliveira Rodrigues, et al.
European Journal of Clinical Pharmacology (2024)
Closed Access | Times Cited: 4
Page 1 - Next Page

Scroll to top